HIV-1 Protease Inhibitor ASC09

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable human immunodeficiency virus type 1 (HIV-1) protease inhibitor, with potential activity against HIV and certain other RNA viruses. Upon oral administration, HIV-1 protease inhibitor ASC09 selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. In addition, ASC09 may also inhibit viral proteases from other RNA viruses, thereby preventing their replication.

**Synonyms:** - ((3aS,4R,6aR)-2,3,3a,4,5,6a-Hexahydrofuro(2,3-b)furan-4-yl) N-((1S,2R)-1-benzyl-3-((2-((1-cyclopentyl-4-piperidyl)amino)-1,3-benzothiazol-6-yl)sulfonyl-isobutyl-amino)-2-hydroxy-propyl)carbamate - ASC 09 - ASC-09 - ASC09 - Carbamic Acid, N-((1S,2R)-3-(((2-((1-cyclopentyl-4-piperidinyl)amino)-6-benzothiazolyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3R,3aS,6aR)-hexahydrofuro(2,3-b)furan-3-yl Ester - Protease Inhibitor ASC09 - TMC 310911 - TMC-310911 - TMC-310911 - TMC310911